KDELR1通过Intergrin-Hippo-YAP1轴调节冠状腺癌的耐药性和恶性行为
Huabin Yin1, Dongjie Jiang2, Yongai Li1
1Department of Orthopedics, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No.85 Wujin Road, Hongkou District, Shanghai, 200080, China.
软骨肉瘤是一种抗化疗的骨癌,显示KDEL受体1 (KDELR1) 表达的增加. 这种KDELR1通路与瘤的攻击性和耐药性有关,提供了潜在的新治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 基因组学就是基因组学.
背景情况:
- 软骨肉瘤 (CS) 是第二常见的原发性骨癌.
- CS表现出独特的转录格局,导致对化疗的耐药性,与骨髓瘤 (OS) 不同.
- 了解CS转录模式对于克服治疗阻力至关重要.
研究的目的:
- 开发一个单细胞转录地图的CS.
- 为了比较CS与OS和正常骨.
- 确定导致CS化疗耐药性的关键基因.
主要方法:
- 单细胞RNA测序以创建转录地图.
- 对CS,OS和正常骨转录组进行比较分析.
- 质谱学蛋白质组学和转录组学以确定分子通路.
主要成果:
- 在CS中,KDEL受体1 (KDELR1) 表达显著增加.
- 升高的KDELR1与CS的不良预后,瘤攻击性和药物耐药性相关.
- 在CS中,KDELR1通过KDELR1-Integrin-PLCγ-YAP1轴调节Hippo-YAP通路.
结论:
- KDELR1-Integrin-PLCγ-YAP1轴是CS中药物耐药性和恶性瘤的关键调解器.
- KDELR1 是一种潜在的治疗瘤治疗瘤治疗标.
- 针对这种途径可以提供克服CS化疗耐药性的新策略.
更多相关视频
10:32Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs
Published on: December 19, 2019
07:16Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor
Published on: September 13, 2018
相关概念视频
Regulation of Angiogenesis and Blood Supply
Abnormal Proliferation
PI3K/mTOR/AKT Signaling Pathway
Activation of Integrins
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
Intracellular Signaling Affects Focal Adhesions
Some...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
